

Inventors: Civelli et al.  
Serial No. 09/780,576  
Filed: February 9, 2001  
Page 11

#### REMARKS

Claims 3, 9, 14, 19, and 46 to 53 are pending in the present application. Claims 54 to 63 have been added herein. Claims 3, 9, 14, 19, 47, 49, 52 and 53 have been amended herein. Thus, upon entry of the present amendment, claims 3, 9, 14, 19, and 46 to 63 will be under examination.

#### Regarding the amendments

Claims 3, 9, 14 and 19 have been amended to recite "one or more" compounds throughout the claims, to be consistent with recitation of the phrase "one or more candidate compounds" recited in step (a). Claims 3, 9, 14 and 19 also have been amended to include a step in which the altered production of a G-protein coupled signal (claims 3 and 14) or altered binding of ADP-glucose receptor to ADP-glucose (claims 9 and 19) is determined. These amendments are supported in the specification, for example, at page 34, line 30 to page 35, line 7, and at page 37, line 28 to page 38, line 16. Further, claims 3, 9, 14 and 19 have been amended to replace the phrase "under conditions wherein said receptor" with "under conditions that permit said receptor." This is a grammatical change that adds no new matter. Claim 3 also has been amended to remove the term "antagonist" throughout; this amendment adds no new matter.

Claims 47, 49, 52 and 53 have been amended to indicate that the receptor is contacted with 2 or more different candidate compounds. This amendment is supported in the specification, for example, at page 37, lines 24-27.

Inventors: Civelli et al.  
Serial No. 09/780,576  
Filed: February 9, 2001  
Page 12

New claims 54, 56, 58 and 60 are parallel to claims 3, 9, 14 and 19, but recite "a candidate compound." New claims 54, 56, 58 and 60 are supported, for example, by claims 3, 9, 14 and 19 as originally filed. These new claims also are supported in the specification, for example, at page 34, line 30 to page 35, line 7, and at page 37, line 28 to page 38, line 16.

New claims 55, 57, 59 and 61 recite that the receptor is contacted with 100 or more compounds separately. These new claims are supported by claims 5, 10, 16 and 20 as originally filed, and by the specification, for example, at page 37, lines 24-27 and page 34, line 30 to page 35, line 7.

New claims 62 and 63 depend from claims 14 and 58, respectively, and are directed to identifying one or more ADP-glucose receptor antagonists (claim 62) or an ADP-glucose receptor antagonist (claim 63). These claims are supported, for example, by claim 14 as originally filed.

As set forth above, the amendments are fully supported by the specification and claims as originally filed and do not introduce new matter. Accordingly, entry of the amendments is respectfully requested.

Inventors: Civelli et al.  
Serial No. 09/780,576  
Filed: February 9, 2001  
Page 13


**CONCLUSION**

In view of the amendments and the remarks submitted herein, Applicants submit that the claims are in condition for allowance and respectfully request a notice to that effect. The Examiner is invited to contact the undersigned agent or Cathryn Campbell if there are any questions relating to this application.

Respectfully submitted,

Date: February 24, 2004

McDERMOTT, WILL & EMERY  
4370 La Jolla Village Drive,  
Suite 700  
San Diego, California 92122

  
Pamela M. Guy  
Registration No. 51,228  
Telephone No. (858) 535-9001  
Facsimile No. (858) 535-8949